Global pharma major Lupin Limited (Lupin) has announced the launch of liraglutide injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pen, in the United States.
Liraglutide injection is bioequivalent to Victoza injection (18 mg/3 mL; 6 mg/mL) from Novo Nordisk Inc. It is indicated as an adjunct to diet and exercise to improve glycaemic control in adults and paediatric patients aged 10 years and older with type 2 diabetes mellitus.
“We are pleased to launch liraglutide injection in the U.S. This marks a significant milestone in expanding our complex injectables portfolio and reinforces our commitment to making essential therapies more accessible for patients.”
Spiro Gavaris, President – U.S. Generics, Lupin.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!